BioXcel Therapeutics Inc.
BTAI | NASDAQ
$0.18
-$0.54 (-74.96%)
Aug 28, 2026, 4:00 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
PE Ratio | -0.28 | -0.25 | -0.48 | -3.63 | -5.01 | -12.19 |
PEG Ratio | 0 | 0 | -0.12 | -0.08 | -0.72 | -0.14 |
PS Ratio | 30.42 | 6.69 | 62.27 | 1.6K | n/a | n/a |
PB Ratio | -0.20 | -0.16 | -1.52 | 7.84 | 2.42 | 4.85 |
P/FCF Ratio | -0.34 | -0.21 | -0.55 | -4.44 | -6.49 | -15.03 |
P/OCF Ratio | -0.34 | -0.21 | -0.55 | -4.45 | -6.53 | -15.10 |
OCF/S Ratio | -8.97K | -3.18K | -11.23K | -36.09K | n/a | n/a |
Debt / Equity Ratio | -1.15 | -1.11 | -1.79 | 1.23 | 0.01 | 0.01 |
Quick Ratio | 0.82 | 1.65 | 2.57 | 6.11 | 14.21 | 18.33 |
Current Ratio | 0.83 | 1.68 | 2.65 | 6.17 | 14.21 | 18.33 |
Asset Turnover | 0.01 | 0.06 | 0.02 | 0 | n/a | n/a |
Interest Coverage | -2.96 | -4.44 | -12.90 | -19.44 | -2.67K | -3.05K |
Return on Equity | 73.22% | 64.02% | 316.86% | -215.90% | -48.24% | -39.75% |
Return on Assets | -155.62% | -155.46% | -242.94% | -80.52% | -44.66% | -37.36% |
Return on Invested Capital | -314.44% | -408.06% | -367.20% | -92.13% | -47.94% | -39.50% |
Dividend Yield | n/a | n/a | n/a | n/a | n/a | n/a |
Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
FCF Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit Margin | 74.45% | 5.43% | 8.70% | 94.67% | n/a | n/a |
Net Profit Margin | -10.89K% | -2.63K% | -12.97K% | -44.2K% | n/a | n/a |
Pretax Profit Margin | -10.89K% | -2.63K% | -12.97K% | -44.2K% | n/a | n/a |
Operating Profit Margin | -7.83K% | -2.97K% | -12.45K% | -42.57K% | n/a | n/a |
FCF Margin | -8.97K% | -3.18K% | -11.23K% | -36.13K% | n/a | n/a |
EBITDA Margin | -8.2K% | -1.95K% | -11.99K% | -41.92K% | n/a | n/a |
Add to Watchlist
Select watchlists to add or remove BTAI